Cheniere Energy vs Smith & Nephew plc — how do they compare? Cheniere Energy trades at $277.71 (market cap $57.39B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Cheniere Energy is far larger — about 5.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Cheniere Energy for 10 Days and Smith & Nephew plc for 121 Days on average.
| LNG | SNN | |
|---|---|---|
Market Cap | $57.39B | $11.10B |
Volume | 1,215,835 | 1,051,703 |
Sector | Energy | Health |
52-Week High | $296.91 | $37.17 |
52-Week Low | $188.83 | $26.42 |
Typical Hold Time | 10 Days | 121 Days |
Enterprise Value | $82.85B | $14.13B |
Dividend Yield | 0.8% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cheniere Energy produces, liquefies, and exports natural gas as liquefied natural gas, or LNG. It operates large-scale LNG infrastructure along the U.S. Gulf Coast.
Read more on LNG →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →